CTLA 4 News and Research

RSS

Immunotherapy shows potential for treating rising gynecological tumors

Gynecological tumors, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC), represent a significant global health burden for women.

1 Sep 2026

Exhausted T cells balance graft tolerance and infection risk

A comprehensive new review examines the complex role of T cell exhaustion in organ transplantation, highlighting how this dysfunctional immune state can both promote graft tolerance and create vulnerabilities to infection and malignancy.

7 Aug 2026

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026

KAIST study opens a new avenue for treating intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

19 Jul 2026

New AI model improves prediction of cancer immunotherapy success

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others.

3 Jul 2026

Pioneering gene therapy for rare immune disorder shows promise in early pre-clinical studies

The development of a pioneering gene therapy to treat a devastating, rare immune disorder led by UCL scientists is set to move into its next phase following promising early pre-clinical studies.

27 Jun 2026

Engineered CAR T cells successfully target bladder cancer in mice

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells.

26 Jun 2026

Review highlights TIGIT as a promising second-generation immunotherapy target

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.

5 Jun 2026

Researchers uncover immune mechanisms behind polycystic kidney disease progression

A new review has illuminated a critical but often overlooked dimension of autosomal dominant polycystic kidney disease (ADPKD)—its immune microenvironment.

24 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Implantable cytokine factories show promise against advanced ovarian cancer

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality.

12 May 2026

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address chronic rejection and carries long-term side effects including infection, malignancy, and metabolic disorders.

8 May 2026

New immunotherapy strategy overcomes resistance in colorectal cancer treatment

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.

6 May 2026

Tumor immune cell patterns predict melanoma immunotherapy response

A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working - and which may not.

22 Apr 2026

New dual drugs eliminate tumors when combined with immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.

2 Apr 2026

Gene signature maps cholangiocarcinoma subtypes for precision treatment

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature.

31 Mar 2026

New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma

The 1,341-gene signature for intrahepatic cholangiocarcinoma offers a framework for precise diagnosis and tailored therapies, addressing tumor heterogeneity.

From BGI Genomics 31 Mar 2026

New insights highlight multifaceted roles of CD4+ T cells in tumor immunity

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell killing.

13 Mar 2026

Combination therapy may help overcome barrier in early-stage prostate cancer treatment

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment.

26 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026